WO2023036349A1 - Uso de anticuerpos monoclonales anti-cd6 en la prevención del daño celular y orgánico derivado de una respuesta hiper-inflamatoria - Google Patents
Uso de anticuerpos monoclonales anti-cd6 en la prevención del daño celular y orgánico derivado de una respuesta hiper-inflamatoria Download PDFInfo
- Publication number
- WO2023036349A1 WO2023036349A1 PCT/CU2022/050010 CU2022050010W WO2023036349A1 WO 2023036349 A1 WO2023036349 A1 WO 2023036349A1 CU 2022050010 W CU2022050010 W CU 2022050010W WO 2023036349 A1 WO2023036349 A1 WO 2023036349A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- mab
- use according
- surgery
- sequences
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 230000005779 cell damage Effects 0.000 title claims abstract description 4
- 230000008816 organ damage Effects 0.000 title claims abstract 3
- 230000028709 inflammatory response Effects 0.000 title description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000004044 response Effects 0.000 claims abstract description 14
- 230000001960 triggered effect Effects 0.000 claims abstract description 6
- 238000001356 surgical procedure Methods 0.000 claims description 31
- 102000004889 Interleukin-6 Human genes 0.000 claims description 28
- 229950003818 itolizumab Drugs 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 18
- 230000006378 damage Effects 0.000 claims description 16
- 208000014674 injury Diseases 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- 238000007675 cardiac surgery Methods 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000002615 hemofiltration Methods 0.000 claims description 6
- 239000002249 anxiolytic agent Substances 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 230000000779 depleting effect Effects 0.000 claims description 4
- -1 emtropoietin Substances 0.000 claims description 4
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 3
- 208000004221 Multiple Trauma Diseases 0.000 claims description 3
- 208000023637 Multiple injury Diseases 0.000 claims description 3
- 230000010398 acute inflammatory response Effects 0.000 claims description 3
- 229940035674 anesthetics Drugs 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940121357 antivirals Drugs 0.000 claims description 3
- 208000021138 brain aneurysm Diseases 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 230000002956 necrotizing effect Effects 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 229940125723 sedative agent Drugs 0.000 claims description 3
- 238000007631 vascular surgery Methods 0.000 claims description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000009467 reduction Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000007423 decrease Effects 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000002980 postoperative effect Effects 0.000 description 7
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 6
- 229960003793 midazolam Drugs 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 4
- 229960002428 fentanyl Drugs 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 210000004115 mitral valve Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003680 myocardial damage Effects 0.000 description 3
- 238000012959 renal replacement therapy Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039203 Road traffic accident Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960001862 atracurium Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002692 epidural anesthesia Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000002321 radial artery Anatomy 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000002802 cardiorespiratory effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940107177 elbasvir / grazoprevir Drugs 0.000 description 1
- SVPWXLXHFSKQRN-QZUDGTEMSA-N elbasvir and grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C.COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C1N=C(C=2C=C3O[C@H](N4C5=CC=C(C=C5C=C4C3=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)C=2C=CC=CC=2)C=N1 SVPWXLXHFSKQRN-QZUDGTEMSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 238000002576 laryngoscopy Methods 0.000 description 1
- 229960002461 ledipasvir Drugs 0.000 description 1
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940076773 lidocaine 70 mg Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000031978 negative regulation of complement activation Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960002091 simeprevir Drugs 0.000 description 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000213 tachycardiac effect Effects 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 206010043827 tibia fracture Diseases 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- 229960000863 velpatasvir Drugs 0.000 description 1
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Definitions
- the present invention relates to the branches of biotechnology and medicine; especially with the use of anti-CD6 monoclonal antibodies (Mabs), the prevention of cellular and organic damage derived from a hyper-inflammatory response that is triggered by, or affects the final result of specific medical procedures.
- Mabs monoclonal antibodies
- extracorporeal organic supports constituted one of the most important advances of the last century in medicine.
- the most frequently used are extracorporeal circulation (ECC) and renal replacement therapies; In both methods there is blood circulation outside the body through artificial circuits.
- ECC extracorporeal circulation
- renal replacement therapies In both methods there is blood circulation outside the body through artificial circuits.
- CPB or cardiopulmonary bypass or heart-lung machine/pump as it is also known, and extracorporeal membrane oxygenation (ECMO) are applied in different circumstances, such as cardiovascular surgery and patient support with severe cardiorespiratory dysfunction.
- Renal replacement therapies dialysis, hemofiltration, hemodiafiltration and others are widely used in acute and chronic failures (Durmaz I et al. (1999), Thorac Cardiovasc Surg. 118:306-315).
- the use of hemodialysis in patients with chronic kidney disease can be accompanied by elevated levels of inflammatory biomarkers such as IL-6 and C-reactive protein (CRP) compatible with a low-grade inflammatory process (Nowak K and Chonchol M (2016) Semin Dial. 31 (4):388-397).
- inflammatory biomarkers such as IL-6 and C-reactive protein (CRP) compatible with a low-grade inflammatory process
- CRP C-reactive protein
- the organism launches a response with an initial inflammatory phase, mediated by humoral and cellular factors that is characterized by being restricted and localized that tends to limit tissue damage; it isolates, destroys and eliminates infectious microorganisms and activates the repair processes necessary for the return of the damaged organ to its normal function.
- humoral and cellular factors that is characterized by being restricted and localized that tends to limit tissue damage; it isolates, destroys and eliminates infectious microorganisms and activates the repair processes necessary for the return of the damaged organ to its normal function.
- monocytes and endothelial cells initially release, in the injured area, a series of pro-inflammatory cytokines.
- TNFa and IL-1 are the first cytokines secreted after trauma, they stimulate various immunocompetent cells and induce the release of pro-inflammatory cytokines (IL-6, IL-8 and gamma interferon).
- Urinary trypsin inhibitor administered intravenously in the trans and postoperative period decreases the concentrations of TNF-a, IL-1p, IL-6, IL-8 and transaminases with a consequent decrease in the duration of ventilation and time of hospitalization in the Intensive Care Unit (ICU), but it is not known whether the decrease in these parameters decreases the morbidity and mortality of treated patients (Xu H et al. (2017) Euro Rev Medical and Pharmacol Se.; 21 : 2220 -2225;G. He, et al.(2018) Herz h tps;//doLorg/10 ⁇ 1007/300059:018-473 -0) .
- Pexelizumab (anti-C5 mAb) also did not show a significant clinical effect in reducing morbidity and mortality and was not free of adverse reactions, among which infections, including sepsis, stand out. (Shernan SK et al. (2004) Ann Thorac Surg. 77:942-50).
- anti-factor D mAb in monkeys subjected to cardiopulmonary bypass demonstrated inhibition of complement activation, CD11b expression on neutrophils and monocytes, as well as a decreased increase in the concentration of IL-6 in plasma, compared to the control group. who did not receive the mAb; as well as markers of myocardial damage and renal function and creatinine.
- no study in humans was found in the reviewed literature where the use of antifactor D mAb demonstrated the effect on the decrease of cytokines, as prevention and modulation of the hyper-inflammatory response that produces the passage of blood through the extracorporeal circuit. nor its consequent cell damage.
- Patent PCT/IB2021/052793 describes the use of non-depleting anti-CD6 mAbs that specifically bind to domain I of CD6 in the treatment of cytokine storm caused by infectious agents such as viruses and bacteria.
- Patients with pneumonia treated with these mAbs showed a reduction in the levels of IL-6, IL-17, TNFa and CRP, which led to an improvement in lung function parameters, preventing them from evolving to critical or severe stages and to a better their management in the ICU.
- the inventors of the present invention when using the MAbs described here in patients requiring CPB or who suffered trauma, achieved a reduction in the degree of hyper-inflammation through a lower concentration of IL-6, CRP, and function markers and organic damage such as LDH and TGP, with the consequent prevention of cellular and organic damage, impacting from the clinical point of view by reducing general morbidity, multiple organ failure and post-operative mortality.
- the present invention is related to the use of mAbs that specifically recognize CD6, in the prevention of cellular and organic damage derived from a hyper-inflammatory response that is triggered by highly invasive medical procedures, or affects the final result of said procedures. procedures.
- these mAbs are non-depleting and specifically bind to domain 1 of CD6.
- These MAbs comprise the sequences SEQ ID NO 1 and 2 or have 98% identity with them and in this case comprise the sequences SEQ ID NO. 1 and SEQ ID NO. 3.
- these mAbs can comprise the sequences SEQ ID NO 4 and 5 or have 98% identity with them and thus comprise SEQ ID NO. 4 and SEQ ID NO. 6.
- these anti-CD6 mAbs are humanized IgG1 isotypes, preferably the itolizumab mAb.
- the present invention relates to the use of the mAbs described herein to prevent cellular and organic damage derived from the following procedures or medical conditions: cardiac surgery, lung transplant surgery, giant brain aneurysm surgery, vascular surgery, oxygenation extracorporeal membrane, mechanical circulatory assistance, hemofiltration, renal dialysis and hemodiafiltration, damage control surgery, trauma, polytrauma, burns, necrotizing peritonitis, acute inflammatory response syndrome, without being limited to these.
- the present invention provides for the combination of anti-CD6 mAbs with agents selected from the group comprising: anesthetics, sedatives, relaxants, antivirals, antibiotics, emtropoietin, agents that block the interaction between IL-6 and the IL-6 receptor and agents that block the interaction between IL1 and the IL1 receptor. Said administration can be carried out signally or concomitantly.
- the present invention relates to a treatment method for a subject undergoing CPB that comprises the intravenous or subcutaneous administration of the MAbs that comprise the amino acid sequences shown in the sequences SEQ ID NO. 1 and 2 or in the sequences SEQ ID NO. 4 and 5 or of the mAbs with an amino acid sequence having 98% identity therewith and comprising the sequences SEQ ID NO. 1 and SEQ ID NO. 3 or the sequences SEQ ID NO. 4 and SEQ ID NO. 6; in a dose range between 0.3 mg/Kg of weight to 6 mg/Kg of weight.
- Said MAbs are administered to the subject at least once, the time that elapses between two consecutive administrations is between three and seven days.
- the MAbs that are used in the present invention are administered as part of pharmaceutical compositions that contain the MAb as active principle and as an appropriate excipient, buffered physiological solution, similar to others used to formulate MAbs for intravenous or subcutaneous use.
- the itolizumab sequences are described in US patent 6,572,857 B1 and 8,524,233 and are shown in detail in Table 1.
- the present invention relates to the use of anti-CD6 mAbs in the prevention of a hyper-inflammatory response that is triggered by, or affects the end result of specific medical procedures, among which are heart surgery, lung transplant surgery , giant brain aneurysm surgery and, vascular surgery, extracorporeal membrane oxygenation (ECMO), mechanical circulatory assistance (MCA), renal replacement therapies such as hemofiltration, therapy or iterated dialysis, hemodiafiltration, control surgery damage, trauma, polytrauma, burns, necrotizing peritonitis, acute inflammatory response syndrome.
- ECMO extracorporeal membrane oxygenation
- MCA mechanical circulatory assistance
- renal replacement therapies such as hemofiltration, therapy or iterated dialysis, hemodiafiltration, control surgery damage, trauma, polytrauma, burns, necrotizing peritonitis, acute inflammatory response syndrome.
- anti-CD6 mAbs whose amino acid sequence is shown in SEQ ID NO. 1 (heavy chain variable region) and SEQ ID NO. 2 (light chain variable region) or with sequences with 98% identity therewith and comprising SEQ ID NO. 1 (heavy chain variable region) and SEQ ID NO.3 (light chain variable region) according to the present invention.
- anti-CD6 mAbs that have heavy and light chain regions comprising the amino acid sequences set forth in SEQ ID NO.4 (heavy chain) and SEQ ID NO.5 (light chain) or with sequences with 98% identity with these according to the present invention.
- An anti-CD6 mAb comprising or consisting of SEQ ID NO: 4 and 6 is included in the present invention.
- non-depleting anti-CD6 Ab means a mAb that recognizes CD6 and that, once it binds to it, does not induce Ab-dependent cellular cytotoxicity (ADCC). complement-dependent cellular cytotoxicity (CDC) or does not otherwise promote lysis or death of CD6-expressing cells. Therefore, an advantage Particular of the proposed treatment is the non-induction of immunodeficiency in the patient, unlike other therapies based on steroids, mAbs or other immunosuppressants. The preservation of certain immuno-competence in the treated patient reduces the possibility of emergency due to other opportunistic infections, very common in intensive care.
- Patients receiving anti-CD6 mAb therapy may be admitted to an intensive care unit, although they may also be in a conventional unit or outpatient clinic.
- Patients receiving anti-CD6 mAb therapy may be admitted to an intensive care unit, although they may also be in a conventional unit or outpatient clinic.
- Adult, pediatric or pregnant patients are eligible for treatment with anti-CD6 mAbs.
- the antibody will be applied to the subjects (these subjects are vertebrates, such as humans), intravenously or subcutaneously, in a dose range between 0.3 mg/Kg of weight and 6 mg/Kg of weight, which correspond between 25 and 420 mg total respectively.
- the antibody will be administered at least once to the patient and the time between two consecutive administrations will be between three and seven days.
- the dose and schedule to be used for different anti-CD6 mAbs may be adjusted by evaluating the concentration of IL-6 or the ability to inhibit in vitro or in vivo the activation of CD6+ T and/or B lymphocytes, or without inducing their elimination. /depletion as in the specific case of mAb itolizumab.
- Anti-CD6 mAbs can be combined with any anesthetic, sedative, relaxant, or antibiotic permitted for human use based on the patient's medical condition.
- Possible antivirals to be combined include, but are not limited to, ribavirin, type 1 and type 2 interferons, as well as protease inhibitors (including but not limited to boceprevir, telaprevir, simeprevir), transcriptase inhibitors reverse (including but not limited to lazidovidine, abacabar, lamivudine, emtricitabine, tenofovir, nevirapine, efavirenz, etravirine), polymerase inhibitors (including but not limited to sofosbuvir, ledipasvir , velpatasvir, saquinavir, ritonavir, indinavir, nelfinavir, lopinavir, atazanovir, fosamprenavir, tipranavir, daruna
- serial or concomitant combination of an anti-CD6 mAb with therapeutic agents that block the interaction between IL-6 and IL-6R or between IL-1 and IL-1R is also an object of the present invention.
- Additional therapy treatments should be short enough to contribute to the reduction of hyperinflammation, but without inducing immunosuppression that facilitates the spread of bacteria and viruses in the patient.
- serial or concomitant combination of an anti-CD6 mAb with erythropoietin is the object of the present invention.
- erythropoietin in particular, in the protection of kidney damage, mainly in patients with a dialysis regimen.
- Figure 1 Inflammatory profile (LDH, IL-6 and CRP concentrations) of a patient treated with itolizumab at a dose of 1.6 mg/kg of weight.
- FIG. 1 Comparison of IL-6 concentrations in patients undergoing surgery with CPB without and with treatment with itolizumab at a dose of 1.6 mg/kg of weight.
- FIG. 1 Hepatic profile (ALT, PAL, and total bilirubin concentrations) of a patient treated with itolizumab at a dose of 1.6 mg/kg of weight. Normal values: ALT ⁇ 40 Ul/L, FAL 39-117 Ul/L, total bilirubin ⁇ 20pg/L.
- FIG. Renal profile (creatinine and urea concentrations) of a patient treated with itolizumab at a dose of 1.6 mg/kg of weight. Normal values of creatinine in men: 62-106 pmol/L and women: 44-80 pmol/L, urea: 1.7-8.3 pmol/L.
- Figure 7 IL-6 and LDH concentrations of a patient treated with itolizumab at a dose of 0.3 mg/kg of weight.
- Figure 8 Comparison of IL-6 concentrations in the different conditions evaluated in comparison with treatment with itolizumab at a dose of 0.3 mg/kg of weight.
- Figure 9. IL-6 and lactate concentration in a post-trauma patient who underwent orthopedic surgery treated with itolizumab at a dose of 1.6 mg/kg of weight. Normal lactate values: 0.5-1.6 mmol/L.
- Example 1 Demonstration of the reduction of the degree of hyperinflammation in a patient with mitral valve replacement surgery and CEC treated with itolizumab (1.6 mg/kg of weight).
- a patient undergoing mitral valve replacement surgery was administered 1.6mg/kg body weight of the mAb itolizumab (100mg) in 250mL saline and 2mg midazolam as anesthetic premedication.
- a cannula was placed in the radial artery for invasive blood pressure monitoring.
- Anesthetic induction was performed with lidocaine 70 mg, fentanyl 350 pg, midazolam 8 mg, followed by atracurium 35 mg.
- Laryngoscopy and easy intubation with an 8.0 endotracheal tube was coupled to an anesthesia machine in volume-controlled ventilation.
- a central venous line was placed by percutaneous puncture of the internal jugular vein. Maintenance was performed with balanced anesthesia with isoflurane and a continuous infusion of fentanyl at a rate of 5pg/kg/h, midazolam 0.15 mg/kg/h, and atracurium 0.2 mg/kg on demand. A 4 mg continuous magnesium solution was administered in one hour.
- Example 2 Demonstration of the reduction of the degree of hyper-inflammation in a patient with mitral valve replacement surgery treated with itolizumab (0.3 mg/kg of weight).
- a patient undergoing mitral valve replacement surgery was administered 0.3 mg/kg body weight of the mAb itolizumab (25 mg) in 50 mL saline and 2 mg midazolam as anesthetic premedication.
- a cannula was placed in the radial artery for invasive blood pressure monitoring.
- Anesthetic induction was performed with 80 mg lidocaine, 400 pg fentanyl, 8 mg midazolam, followed by 40 mg atracuno. Langoscopy and easy intubation with an 8.5 endotracheal tube, was coupled to an anesthesia machine in volume-controlled ventilation.
- a central venous line was placed by percutaneous puncture of the internal jugular vein. Maintenance was performed with balanced anesthesia with isofluorane and a continuous infusion of fentanyl at a rate of 5 pg/kg/h, midazolam 0.15 mg/kg/h and atracunio 0.2 mg/kg on demand. A continuous 4mg magnesium solution was administered in one hour. Uncomplicated sternal opening. The ascending aorta and superior and inferior vena cava were cannulated. After 5mg/kg heparinization, CPB was started and a mean flow between 1.8 and 2.4 L/m 2 of body surface was maintained, with a mean arterial pressure between 60 and 70 mmHg.
- Aorta was clamped and hyperkalemic cardioplegia was used for myocardial protection. Prosthetic valve replacement was performed without complications.
- Aortic clamp time 71 minutes. Active patient in sinus rhythm. Internal environment normal, vital signs within physiological parameters, came out of bypass without hemodynamic support. CEC time 95 minutes. Heparin is reversed.
- Treatment with itolizumab attenuated the inflammatory response observed in monitoring the concentration of IL-6 and PCR; which evidenced prevention of cellular and organic damage.
- Example 3 Demonstration of the reduction of the degree of hyper-inflammation prior to surgery in a patient who suffered a traffic accident.
- a patient who suffered a traffic accident was received at the hospital approximately 1 hour later, conscious with great psychomotor agitation, clear and coherent language with pentraumatic amnesia, with stigmata of frontal cranial trauma, and multiple friction burns on the upper limbs. and left shoulder region.
- Respiratory system preserved chest expansibility, no trauma stigma, preserved vesicular murmur, no rales, respiratory rate: 23/min.
- Cardiovascular pale sweaty patient with generalized coldness of skin. Good tone rhythmic tachycardic sounds heart rate 102/min. Abdomen smooth, depressible, painless, no peritoneal reaction.
- Retrograde locked intramedullary nailing of the femur fracture and non-retained locked intramedullary nailing of the tibia fracture were performed using a single infrapatellar approach with a surgical time of 1 h 27 min.
- Serum samples were taken for the determination of IL-6 concentration at: 1 ;3; 6; 12 and 24 hours after the accident.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3231281A CA3231281A1 (en) | 2021-09-08 | 2022-09-01 | Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper-inflammatory response |
KR1020247011767A KR20240055093A (ko) | 2021-09-08 | 2022-09-01 | 과다 염증 반응으로 인한 세포 및 장기 손상 예방을 위한 항-cd6 단일클론항체의 용도 |
AU2022344418A AU2022344418A1 (en) | 2021-09-08 | 2022-09-01 | Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response |
IL311287A IL311287A (en) | 2021-09-08 | 2022-09-01 | Use of anti-CD6 monoclonal antibodies in the prevention of damage to cells and organs as a result of a hyper-inflammatory reaction |
MX2024002900A MX2024002900A (es) | 2021-09-08 | 2022-09-01 | Uso de anticuerpos monoclonales anti-cd6 en la prevencion del da?o celular y organico derivado de una respuesta hiper-inflamatoria. |
CN202280060524.2A CN117980337A (zh) | 2021-09-08 | 2022-09-01 | 抗cd6单克隆抗体在预防由高炎症反应引起的细胞和器官损伤中的用途 |
EP22797264.3A EP4400513A1 (en) | 2021-09-08 | 2022-09-01 | Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20210074 | 2021-09-08 | ||
CU2021-0074 | 2021-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023036349A1 true WO2023036349A1 (es) | 2023-03-16 |
Family
ID=84044116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2022/050010 WO2023036349A1 (es) | 2021-09-08 | 2022-09-01 | Uso de anticuerpos monoclonales anti-cd6 en la prevención del daño celular y orgánico derivado de una respuesta hiper-inflamatoria |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4400513A1 (es) |
KR (1) | KR20240055093A (es) |
CN (1) | CN117980337A (es) |
AU (1) | AU2022344418A1 (es) |
CA (1) | CA3231281A1 (es) |
IL (1) | IL311287A (es) |
MX (1) | MX2024002900A (es) |
WO (1) | WO2023036349A1 (es) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572857B1 (en) | 1995-11-17 | 2003-06-03 | Centro De Inmunologia Molecular (Cim) | Anti-CD6 monoclonal antibodies and their uses |
US8524233B2 (en) | 2008-03-14 | 2013-09-03 | Biocon Limited & Centro de Immunologia Molecular | Monoclonal antibody and a method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3100697B1 (fr) | 2019-09-16 | 2022-11-25 | Oreal | Nuancier et procédé de fabrication d’un tel nuancier |
-
2022
- 2022-09-01 WO PCT/CU2022/050010 patent/WO2023036349A1/es active Application Filing
- 2022-09-01 IL IL311287A patent/IL311287A/en unknown
- 2022-09-01 AU AU2022344418A patent/AU2022344418A1/en active Pending
- 2022-09-01 CA CA3231281A patent/CA3231281A1/en active Pending
- 2022-09-01 CN CN202280060524.2A patent/CN117980337A/zh active Pending
- 2022-09-01 EP EP22797264.3A patent/EP4400513A1/en active Pending
- 2022-09-01 KR KR1020247011767A patent/KR20240055093A/ko unknown
- 2022-09-01 MX MX2024002900A patent/MX2024002900A/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572857B1 (en) | 1995-11-17 | 2003-06-03 | Centro De Inmunologia Molecular (Cim) | Anti-CD6 monoclonal antibodies and their uses |
US8524233B2 (en) | 2008-03-14 | 2013-09-03 | Biocon Limited & Centro de Immunologia Molecular | Monoclonal antibody and a method thereof |
Non-Patent Citations (18)
Title |
---|
COBO G, NEPHROL DIAL TRANSPLANT, vol. 33, 2018, pages 35 - 40 |
DURMAZ I, THORAC CARDIOVASC SURG, vol. 118, 1999, pages 306 - 315 |
G. HE, HERZ, 2018, Retrieved from the Internet <URL:https://doi.org/10.1007/s00059-018-4732-0> |
GRAHAM EM, J AM COLL CARDIOL, vol. 74, no. 5, 2019, pages 659 - 668 |
LOMIVOROTOV V, JAMA, vol. 323, no. 24, 2020, pages 2485 - 2492 |
MENGER MICHAEL D. ET AL: "Surgical trauma: hyperinflammation versus immunosuppression?", LANGENBECK'S ARCHIVES OF SURGERY, vol. 389, no. 6, 1 November 2004 (2004-11-01), DE, pages 475 - 484, XP093001776, ISSN: 1435-2443, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s00423-004-0472-0.pdf> [retrieved on 20221125], DOI: 10.1007/s00423-004-0472-0 * |
MOLINA MÉNDEZ FJ, ARCH CARDIOL MEX, vol. 74, no. S-2, 2004, pages 505 - 508 |
NOWAK KCHONCHOL M, SEMIN DIAL, vol. 31, no. 4, 2018, pages 388 - 397 |
P THACKER HEMANT ET AL: "An early experience of Itolizumab with best supportive care in the treatment of moderate to severe COVID-19 patients: A retrospective study", IP INDIAN JOURNAL OF IMMUNOLOGY AND RESPIRATORY MEDICINE, vol. 6, no. 1, 28 February 2021 (2021-02-28), pages 24 - 28, XP093001801, ISSN: 2581-4214, Retrieved from the Internet <URL:https://www.ijirm.org/journal-article-file/13314> [retrieved on 20221125], DOI: 10.18231/j.ijirm.2021.005 * |
PASQUALI SK, PEDIATRICS, vol. 129, no. 2, 2012, pages e385 - e391 |
RIBOT S, J THORAC CARDIOVASC SURG, vol. 62, 1971, pages 59 - 62 |
SAAVEDRA DANAY ET AL: "An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients", IMMUNITY & AGEING, vol. 17, no. 1, 1 December 2020 (2020-12-01), XP093001793, Retrieved from the Internet <URL:https://d-nb.info/1224120949/34> [retrieved on 20221125], DOI: 10.1186/s12979-020-00207-8 * |
SHERNAN SK, ANN THORAC SURG, vol. 77, 2004, pages 942 - 50 |
SUÁREZ GONZALO L, MED INTENSIVA, vol. 26, no. 6, 2002, pages 292 - 303 |
TANAKA T, IMMUNOTHERAPY, vol. 8, no. 8, 2016, pages 959 - 970 |
UYAR IS, CARDIOVASC J AFR, vol. 24, 2013, pages 322 - 326 |
WHITLOCK RP, LANCET, vol. 386, no. 10000, 2015, pages 1243 - 1253 |
XU H, EURO REV MEDICAL AND PHARMACOL SC., vol. 21, 2017, pages 2220 - 2225 |
Also Published As
Publication number | Publication date |
---|---|
KR20240055093A (ko) | 2024-04-26 |
AU2022344418A1 (en) | 2024-04-04 |
EP4400513A1 (en) | 2024-07-17 |
CA3231281A1 (en) | 2023-03-16 |
MX2024002900A (es) | 2024-04-05 |
IL311287A (en) | 2024-05-01 |
CN117980337A (zh) | 2024-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maslach-Hubbard et al. | Extracorporeal membrane oxygenation for pediatric respiratory failure: history, development and current status | |
Biscotti et al. | ECMO as bridge to lung transplant. | |
von Segesser et al. | Prevention and therapy of leg ischaemia in extracorporeal life support and extracorporeal membrane oxygenation with peripheral cannulation. | |
Tseng et al. | Venoarterial extracorporeal life support in post-traumatic shock and cardiac arrest: lessons learned | |
Park et al. | First-year experience of a Brazilian tertiary medical center in supporting severely ill patients using extracorporeal membrane oxygenation | |
RU2336096C1 (ru) | Способ лечения гепатита с | |
Cancio et al. | Burn resuscitation | |
WO2023036349A1 (es) | Uso de anticuerpos monoclonales anti-cd6 en la prevención del daño celular y orgánico derivado de una respuesta hiper-inflamatoria | |
JP2024534975A (ja) | 過剰炎症反応に起因する細胞および臓器の損傷の予防における抗cd6モノクローナル抗体の使用 | |
RU2302239C1 (ru) | Способ фармакологической коррекции ишемии конечности | |
Kozhakhmetov et al. | Modern principles of treatment of acute destructive pancreatitis | |
Kornelyuk et al. | Extracorporeal membrane oxygenation and modern detoxification techniques in a puerpera with viral and bacterial pneumonia caused by flu a (H1N1) virus | |
RU2302234C2 (ru) | Способ защиты нижней половины туловища от ишемии | |
Vidmar et al. | Extracorporeal membranous oxygenation (ECMO) in neonates and children experiences of a multidisciplinary paediatric intensive care unit | |
RU2357736C1 (ru) | Способ лечения асептического некроза головки бедренной кости и болезни пертеса | |
Watson et al. | 1298: Central Extracorporeal Membrane Oxygenation Support for Disseminated Blastomycosis Septic Shock | |
RU2371122C2 (ru) | Способ лечения острой ишемии конечностей | |
Sharma et al. | A typical procedure an atypical outcome: a rare case of life threatening splenic hemorrhage following colonoscopy | |
Church et al. | The artificial placenta rescues premature lambs from Ventilatory failure | |
Kubisa et al. | Veno-venous extracorporeal membrane oxygenation in a patient with severe acute respiratory failure–case report | |
Moriles et al. | Multi-vessel Ischemia: A Rare Manifestation of Polymyositis | |
Naser et al. | Acute Hypoxic Respiratory Failure Due to CTEPH Managed With Awake Veno-venous ECMO | |
Tanyildiz et al. | Management of an Earthquake in a Pediatric Intensive Care Unit. | |
Liu et al. | Bi-Directional Cannulation of the PTA for Lower Extremity Ischemia during pVA-ECMO: A Case Report | |
Youn et al. | Trauma-induced capillary leak syndrome after penetrating chest injury: Manifestation of massive ascites and pulmonary secretions aggravated by transfusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22797264 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401001431 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 311287 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280060524.2 Country of ref document: CN Ref document number: 3231281 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2024515472 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024004144 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022344418 Country of ref document: AU Ref document number: AU2022344418 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202401338T Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 2022344418 Country of ref document: AU Date of ref document: 20220901 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20247011767 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 809940 Country of ref document: NZ Ref document number: 2022797264 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022797264 Country of ref document: EP Effective date: 20240408 |
|
ENP | Entry into the national phase |
Ref document number: 112024004144 Country of ref document: BR Kind code of ref document: A2 Effective date: 20240229 |